Mary Grecco

DocwireNews

IO in combination with platinum chemotherapy has become the standard of care (SOC) for first-line treatment of patients with advanced NSCLC. Although there are limited second-line treatment options for patients who have progressed on first-line platinum chemotherapy/IO combination therapy, real-world data are limited. Results of a study that evaluated second-line treatment patterns and clinical outcomes in the United States were presented at the 2023 North America Conference on Lung Cancer.
The study consisted of 539 patients with advanced NSCLC who progressed on first-line platinum chemotherapy/IO treatment and were grouped according to second-line treatment category, including taxane monotherapy and combination therapy and nontaxane monotherapy, and by second-line treatment: docetaxel monotherapy, docetaxel plus ramucirumab combination therapy, and gemcitabine monotherapy. The median age at second-line treatment was 68 years, and 78% had nonsquamous histology. The researchers assessed OS, TTD, and time to next treatment (TTNT) using Kaplan-Meier methods from the start of second-line treatment.
Results showed that the majority of patients received docetaxel plus ramucirumab combination therapy (45.1%), followed by docetaxel monotherapy (18.9%) and gemcitabine monotherapy (14.1%). The researchers found median OS to be comparable across the three treatments. Median TTD and TTNT outcomes were also comparable across the three treatments. Patients with fewer (≤4 vs ³8) administrations of prior IO treatment (median OS, 5.0 months vs 7.8 months) and ECOG PS ³2 versus 0-1 (median OS, 4.5 months vs 6.8 months) had significantly shorter survival on second-line treatment.
“This study describes the limited treatment options and the poor prognosis of patients with advanced NSCLC in the real world who are treated with the current standard of care treatments in [the second line] after prior [first-line] platinum chemotherapy/IO combination therapy, emphasizing the need for new treatments in this setting,” the researchers concluded.
Source: Daniel D, Mhatre SK, Carroll C, Patel R, Park J, Haggstrom D. Treatment patterns and outcomes in second-line advanced NSCLC treated after prior platinum chemotherapy and immunotherapy combination therapy: a real-world study. Abstract of a poster presented at the 2023 North America Conference on Lung Cancer; December 1-3, 2023; Chicago, Illinois.

Jordana Jampel

New Findings in Breast Cell Chromosomes May Challenge Early Disease Detection, Benefit Other Organ Disease Detection

Breast Cancer News

Rob Dillard

Assessing the Relationship Between Cardiac Implantable Electronic Devices, Tricuspid Regurgitation

AHA 2024

Emily Menendez

Tumor Treating Fields With Gemcitabine, Nab-Paclitaxel Improve OS in Advanced Pancreatic Cancer

Pancreatic Cancer

Latest News

Treatment Patterns, Outcomes in Second-line Advanced NSCLC Treated After Prior Platinum Chemotherapy/IO Combination Therapy

Non-Small Cell Lung Cancer

A study evaluated second-line treatment patterns and clinical outcomes of IO in NSCLC.

Treatment Patterns, Outcomes in Second-line Advanced NSCLC Treated After Prior Platinum Chemotherapy

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe